PET imaging of tumor-associated macrophages with 89Zr-labeled high-density lipoprotein nanoparticles

Journal of Nuclear Medicine

Volumn 56, Issue 8, 2015, Pages 1272-1277

  Pérez Medina, Carlos ^a,b,c   Tang, Jun ^c,d   Abdel Atti, Dalya ^d   Hogstad, Brandon ^c   Merad, Miriam ^c   Fisher, Edward A ^e   Fayad, Zahi A ^c   Lewis, Jason S ^d,f   Mulder, Willem J M ^c,g   Reiner, Thomas ^d,f  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

89Zr; Breast cancer; Highdensity lipoprotein; PET; Tumor associated macrophages

Indexed keywords

APOLIPOPROTEIN A1; DEFEROXAMINE; HIGH DENSITY LIPOPROTEIN; NANOPARTICLE; PHOSPHOLIPID; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; EX VIVO STUDY; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DISEASE MODEL; MACROPHAGE; METABOLISM; NANOTECHNOLOGY; PROGNOSIS; TISSUE DISTRIBUTION;

ANIMALS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; LIPOPROTEINS, HDL; MACROPHAGES; MICE; NANOPARTICLES; NANOTECHNOLOGY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOISOTOPES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; ZIRCONIUM;

EID: 84938822138     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.158956     Document Type: Article

References (32)

1. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013;23:277-286.
2. Tang X. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 2013;332:3-10.
3. Mantovani A, Locati M. Tumor-associated macrophages as a paradigm of mac-rophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol. 2013;33:1478-1483.
4. Chen Q, Zhang XH, Massague J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell. 2011;20:538-549.
5. Franklin RA, Liao W, Sarkar A, et al. The cellular and molecular origin of tumor-associated macrophages. Science. 2014;344:921-925.
6. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta. 2009;1796:11-18.
7. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263-266.
8. Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25:846-859.
9. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49-61.
10. Zhang QW, Liu L, Gong CY, et al. Prognostic significance of tumor-associated macro-phages in solid tumor: a meta-analysis of the literature. PLoS ONE. 2012;7:e50946.
11. Weissleder R, Nahrendorf M, Pittet MJ. Imaging macrophages with nanopar-ticles. Nat Mater. 2014;13:125-138.
12. Daldrup-Link H, Coussens LM. MR imaging of tumor-associated macrophages. Onco Immunology. 2012;1:507-509.
13. Leimgruber A, Berger C, Cortez-Retamozo V, et al. Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanopar-ticle. Neoplasia. 2009;11:459-468.
14. 64Cu liposomes. Biomaterials. 2012;33:7785-7793.
15. Movahedi K, Schoonooghe S, Laoui D, et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012;72:4165-4177.
16. Skajaa T, Cormode DP, Falk E, Mulder WJ, Fisher EA, Fayad ZA. High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:169-176.
17. Duivenvoorden R, Tang J, Cormode DP, et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun. 2014;5:3065.
18. Tang J, Lobatto ME, Hassing S, et al. Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Sci Adv. 2015;1:e1400223.
19. Vosjan MJ, Perk LR, Visser GW, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunc-tional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5: 739-743.
20. Marcel YL, Ouimet M, Wang MD. Regulation of cholesterol efflux from macro-phages. Curr Opin Lipidol. 2008;19:455-461.
21. Pérez-Medina C, Abdel-Atti D, Zhang Y, et al. A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting. J Nucl Med. 2014;55:1706-1711.
22. Chen B, Ren X, Neville T, et al. Apolipoprotein AI tertiary structures determine stability and phospholipid-binding activity of discoidal high-density lipoprotein particles of different sizes. Protein Sci. 2009;18:921-935.
23. Illingworth DR, Portman OW. Exchange of phospholipids between low and high density lipoproteins of squirrel monkeys. J Lipid Res. 1972;13:220-227.
24. Marsh JB, Welty FK, Schaefer EJ. Stable isotope turnover of apolipoproteins of high-density lipoproteins in humans. Curr Opin Lipidol. 2000;11:261-266.
25. Glass CK, Pittman RC, Keller GA, Steinberg D. Tissue sites of degradation of apoprotein A-I in the rat. J Biol Chem. 1983;258:7161-7167.
26. Braschi S, Neville TA, Maugeais C, Ramsamy TA, Seymour R, Sparks DL. Role of the kidney in regulating the metabolism of HDL in rabbits: evidence that iodination alters the catabolism of apolipoprotein A-I by the kidney. Biochemistry. 2000;39:5441-5449.
27. Dallinga-Thie GM, Van 't Hooft FM, Van Tol A. Tissue sites of degradation of high density lipoprotein apolipoprotein A-IV in rats. Arteriosclerosis. 1986;6: 277-284.
28. Hammad SM, Barth JL, Knaak C, Argraves WS. Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J Biol Chem. 2000;275:12003-12008.
29. Krikken JA, Gansevoort RT, Dullaart RP. Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease. J Lipid Res. 2010;51:1982-1990.
30. Zeglis BM, Mohindra P, Weissmann GI, et al. Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. Bioconjug Chem. 2011;22: 2048-2059.
31. 89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors. Pharmaceuticals (Basel). 2012;5:79-93.
32. 89Zr in mice. Nucl Med Biol. 2011;38:675-681.